-
EP3856169
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3856169
| EP3856169 - METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 02.07.2021 Database last updated on 14.06.2024 | |
| Former | The international publication has been made Status updated on 05.04.2020 | Most recent event Tooltip | 25.08.2023 | New entry: Renewal fee paid | Applicant(s) | For all designated states Impact Biomedicines, Inc. 86 Morris Avenue Summit, New Jersey 07901 / US | [2021/31] | Inventor(s) | 01 /
BERRY, Tymara 22 Bradwahl Drive Morristown, New Jersey 07960 / US | 02 /
HOOD, John 100 Stratford Court Del Mar, California 92014 / US | 03 /
JAMIESON, Catriona 7400 Hillside Drive La Jolla, California 92037 / US | 04 /
SCRIBNER, Curtis L. 4287 Howe Street Oakland, California 94611 / US | [2021/31] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [2021/31] | Application number, filing date | 19866319.7 | 24.09.2019 | [2021/31] | WO2019US52608 | Priority number, date | US201862736369P | 25.09.2018 Original published format: US 201862736369 P | US201862783076P | 20.12.2018 Original published format: US 201862783076 P | [2021/31] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2020068755 | Date: | 02.04.2020 | Language: | EN | [2020/14] | Type: | A1 Application with search report | No.: | EP3856169 | Date: | 04.08.2021 | Language: | EN | The application published by WIPO in one of the EPO official languages on 02.04.2020 takes the place of the publication of the European patent application. | [2021/31] | Search report(s) | International search report - published on: | US | 02.04.2020 | (Supplementary) European search report - dispatched on: | EP | 27.05.2022 | Classification | IPC: | A61K31/198, A61K31/715, A61K33/14, A61K31/51, A61K31/635, A61K31/675, A61K33/06, A61P35/02, A61K9/00 | [2022/26] | CPC: |
A61K31/635 (EP,IL);
A61K31/506 (KR);
A61K31/51 (EP,IL,KR,US);
A61K31/675 (EP,IL,US);
A61K33/06 (EP,IL);
A61P35/02 (EP,IL,KR,US);
A61K2300/00 (IL,KR)
(-)
| C-Set: |
A61K31/51, A61K2300/00 (EP);
A61K31/635, A61K2300/00 (EP);
A61K31/675, A61K2300/00 (EP);
A61K33/06, A61K2300/00 (EP) |
| Former IPC [2021/31] | A61K31/198, A61K31/715, A61K33/14 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/31] | Extension states | BA | 23.04.2021 | ME | 23.04.2021 | Validation states | KH | 23.04.2021 | MA | 23.04.2021 | MD | 23.04.2021 | TN | 23.04.2021 | Title | German: | VERFAHREN ZUR BEHANDLUNG VON MYELOPROLIFERATIVEN ERKRANKUNGEN | [2021/31] | English: | METHODS OF TREATING MYELOPROLIFERATIVE DISORDERS | [2021/31] | French: | PROCÉDÉS DE TRAITEMENT DE TROUBLES MYÉLOPROLIFÉRATIFS | [2021/31] | Entry into regional phase | 23.04.2021 | National basic fee paid | 23.04.2021 | Search fee paid | 23.04.2021 | Designation fee(s) paid | 23.04.2021 | Examination fee paid | Examination procedure | 23.04.2021 | Examination requested [2021/31] | 19.12.2022 | Amendment by applicant (claims and/or description) | Fees paid | Renewal fee | 15.09.2021 | Renewal fee patent year 03 | 11.08.2022 | Renewal fee patent year 04 | 24.08.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [A] - ZHANG QIANG ET AL, "The Janus Kinase 2 Inhibitor Fedratinib Inhibits Thiamine Uptake: A Putative Mechanism for the Onset of Wernicke's Encephalopathy", DRUG METABOLISM AND DISPOSITION, US, vol. 42, no. 10, doi:10.1124/dmd.114.058883, ISSN 0090-9556, (20141027), pages 1656 - 1662, URL: http://dx.doi.org/10.1124/dmd.114.058883, XP055920013 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1124/dmd.114.058883 | [T] - TALPAZ MOSHE ET AL, "Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis", LEUKEMIA, (20200709), vol. 35, no. 1, doi:10.1038/S41375-020-0954-2, ISSN 0887-6924, pages 1 - 17, XP037330089 [T] 1-15 * abstract * DOI: http://dx.doi.org/10.1038/s41375-020-0954-2 | [T] - MULLALLY ANN ET AL, "Fedratinib in myelofibrosis", BLOOD ADVANCES, vol. 4, no. 8, doi:10.1182/bloodadvances.2019000954, ISSN 2473-9529, (20200428), pages 1792 - 1800, URL: http://ashpublications.org/bloodadvances/article-pdf/4/8/1792/1749506/advancesadv2019000954c.pdf, XP055919959 [T] 1-15 * page 1795, column second - page 1796, column first * DOI: http://dx.doi.org/10.1182/bloodadvances.2019000954 | [A] - M. M. GIACOMINI ET AL, "Interaction of 2,4-Diaminopyrimidine-Containing Drugs Including Fedratinib and Trimethoprim with Thiamine Transporters", DRUG METABOLISM AND DISPOSITION, US, (20161216), vol. 45, no. 1, doi:10.1124/dmd.116.073338, ISSN 0090-9556, pages 76 - 85, XP055444055 [A] 1-15 * abstract * DOI: http://dx.doi.org/10.1124/dmd.116.073338 | International search | [A]US2007191405 (NORONHA GLENN [US], et al) [A] 1-4, 6-7, 9-23, 35-40 * ; entire document *; | [Y]US2013102624 (SCHLOSS JOHN V [US]) [Y] 7, 9-23 * ; para[0030] *; | [Y]US2013243853 (JAYAN ARVIND [US], et al) [Y] 1-4, 6 * ; Abstract para[0003] *; | [A]US2016332993 (BRADNER JAMES E [US], et al) [A] 1-4, 6-7, 9-23, 35-40* ; entire document *; | [XY] - PARDANANI et al., "Safety and Efficacy of Fedratinib in Patients With Primary or Secondary Myelofibrosis", JAMA Oncology, (20150618), vol. 1, pages 643 - 651, XP055701880 [X] 35-39 [Y] 40 DOI: http://dx.doi.org/10.1001/jamaoncol.2015.1590 | [Y] - CURTO-GARCIA et al., "Thiamine deficiency appears uncommon in patients with Myeloproliferative Neoplasms", British Journal of Haematology, (20160502), vol. 178, pages 338 - 340, XP055701883 [Y] 1-4, 6-7, 9-23, 40 DOI: http://dx.doi.org/10.1111/bjh.14128 |